FR2942409A1 - Use of at least one protease inhibitor for the prevention of primary or secondary amenorrhea, infertility, repeated abortions and eating disorders, where the disorders are e.g. associated with atypical/frustrated with celiac disease - Google Patents
Use of at least one protease inhibitor for the prevention of primary or secondary amenorrhea, infertility, repeated abortions and eating disorders, where the disorders are e.g. associated with atypical/frustrated with celiac disease Download PDFInfo
- Publication number
- FR2942409A1 FR2942409A1 FR0951105A FR0951105A FR2942409A1 FR 2942409 A1 FR2942409 A1 FR 2942409A1 FR 0951105 A FR0951105 A FR 0951105A FR 0951105 A FR0951105 A FR 0951105A FR 2942409 A1 FR2942409 A1 FR 2942409A1
- Authority
- FR
- France
- Prior art keywords
- disorders
- primary
- use according
- atypical
- frustrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title claims abstract description 21
- 206010000210 abortion Diseases 0.000 title claims abstract description 15
- 231100000176 abortion Toxicity 0.000 title claims abstract description 15
- 206010001928 Amenorrhoea Diseases 0.000 title claims abstract description 9
- 230000036512 infertility Effects 0.000 title claims abstract description 7
- 201000000736 Amenorrhea Diseases 0.000 title claims abstract description 5
- 208000030814 Eating disease Diseases 0.000 title claims abstract description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 title claims abstract description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title claims abstract description 5
- 231100000540 amenorrhea Toxicity 0.000 title claims abstract description 5
- 208000000509 infertility Diseases 0.000 title claims abstract description 5
- 235000014632 disordered eating Nutrition 0.000 title claims abstract description 4
- 208000015943 Coeliac disease Diseases 0.000 title claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 3
- 231100000535 infertility Toxicity 0.000 title abstract description 3
- 230000002265 prevention Effects 0.000 title abstract description 3
- 208000035475 disorder Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 claims description 16
- 230000002068 genetic effect Effects 0.000 claims description 13
- 230000007170 pathology Effects 0.000 claims description 13
- 230000001900 immune effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 claims description 3
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims description 3
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000021267 infertility disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 2
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 10
- 208000000995 spontaneous abortion Diseases 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 3
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 101710181757 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase Proteins 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 101710094863 Acireductone dioxygenase Proteins 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010068237 Hypertransaminasaemia Diseases 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
La présente invention concerne l'utilisation de nouveaux composés destinés, notamment, à la prévention des avortements à répétition. The present invention relates to the use of novel compounds intended in particular for the prevention of repetitive abortions.
On considère qu'on se trouve en présence d'un problème d'avortements à répétition lorsque la femme a subi trois fausses couches. En fait, il convient de considérer comme présentant un risque anormalement élevé de récidive une patiente qui, n'ayant fait qu'une fausse couche, a dépassé l'âge de 35 ans. Le phénomène de fausses couches à répétition peut être lié à un grand nombre de causes qui peuvent être, notamment, génétiques, utérines, hormonales, masculines, infectieuses. Un certain nombre d'entre elles sont d'origine immunologique, elles sont d'ailleurs majoritaires lors des premières semaines de grossesse et deviennent minoritaires par la suite. Les traitements correspondants comportent, par exemple, l'utilisation de médicaments modifiant l'hémostase, de médicaments immunosuppresseurs, éventuellement on a même recours à la transfusion de leucocytes paternels. Aucun de ces traitements ne s'est révélé totalement satisfaisant dans le traitement des fausses couches à répétition et des pathologies associées : stérilité et aménorrhées. It is considered that there is a problem of repeated abortions when the woman has had three miscarriages. In fact, a patient who has had a miscarriage and is over 35 years of age should be considered as having an abnormally high risk of recurrence. The phenomenon of repeated miscarriages can be linked to a large number of causes that can be, in particular, genetic, uterine, hormonal, masculine, infectious. A certain number of them are of immunological origin, they are moreover majority in the first weeks of pregnancy and become minority later. The corresponding treatments include, for example, the use of drugs modifying hemostasis, immunosuppressive drugs, possibly even the transfusion of paternal leukocytes. None of these treatments was found to be completely satisfactory in the treatment of recurrent miscarriages and associated pathologies: infertility and amenorrhea.
L'implication de protéases dans les phénomènes d'avortements à répétition n'a jamais été réellement envisagée. Or c'est précisément l'une des observations qui a conduit à la présente invention, à savoir que les traitements mettant en oeuvre des inhibiteurs de protéases permettaient de prévenir et éventuellement d'empêcher les avortements à répétition ainsi que les pathologies associées, notamment lorsque ceux-ci ont des origines génétiques et/ou immunologiques. De même, les troubles du comportement alimentaire (TCA) tels que l'anorexie ou la boulimie lorsqu'ils ont une origine génétique et/ou immunologique peuvent être améliorés par l'utilisation des inhibiteurs de protéases. Il est apparu que les pathologies en cause, notamment les pathologies gynécologiques et les troubles de l'alimentation, en particulier lorsque ces pathologies sont liées à des facteurs génétiques, pourraient avoir des origines variées dans le système immunitaire et que l'action des anti protéases permettrait de réguler les anomalies génétiques à l'origine de ces pathologies. Dans le traitement des anorexies et des boulimies d'origine génétique, l'utilisation d'anti protéases peut permettre de limiter l'utilisation des antidépresseurs qui constituent encore actuellement la principale thérapie dans le domaine des TCA. Comme dans le cas des pathologies gynécologiques d'origine génétique évoquées précédemment les anti protéases semblent présenter une action sur le système immunitaire. Plus particulièrement, la présente invention concerne l'utilisation d'au moins un composé inhibiteur de protéases pour la fabrication d'un médicament destiné à prévenir et/ou à traiter les aménorrhées primaires ou secondaires, les stérilités et/ou les avortements à répétition et plus particulièrement lorsque ces pathologies sont liées à des causes d'origine génétique, immunologique et notamment à des formes atypiques ou frustres de la maladie coeliaque. The involvement of proteases in repetitive abortion phenomena has never really been considered. It is precisely one of the observations that led to the present invention, namely that treatments using protease inhibitors made it possible to prevent and possibly prevent repeated abortions as well as the associated pathologies, especially when these have genetic and / or immunological origins. Similarly, eating behavior disorders (ARDs) such as anorexia or bulimia when they have a genetic and / or immunological origin can be improved by the use of protease inhibitors. It appeared that the pathologies involved, including gynecological pathologies and eating disorders, particularly when these pathologies are linked to genetic factors, could have various origins in the immune system and the action of anti proteases would regulate the genetic abnormalities that cause these pathologies. In the treatment of anorexia and bulimia of genetic origin, the use of anti proteases may limit the use of antidepressants, which are still the main therapy in the field of TCA. As in the case of gynecological pathologies of genetic origin mentioned above, anti proteases seem to have an action on the immune system. More particularly, the present invention relates to the use of at least one protease inhibitor compound for the manufacture of a medicament for preventing and / or treating primary or secondary amenorrhoea, sterility and / or repeated abortions and especially when these pathologies are linked to causes of genetic origin, immunological and especially to atypical or frustrated forms of celiac disease.
De préférence, les protéines utilisées sont des inhibiteurs de protéases anti HIV. On peut également utiliser d'autres types d'inhibiteurs de protéases, notamment les inhibiteurs actifs anti HCV. Ces produits qui sont actuellement commercialisés essentiellement dans les trithérapies anti HIV se sont révélés, dans une étude préliminaire portant sur des femmes à avortements répétés, avoir des effets significatifs quant à la diminution de ces fausses couches en rétablissant une fécondité normale. Dans le domaine du traitement des TCA lorsque ceux-ci sont d'origine génétique, notamment ayant une composante immunologique, on note une diminution nette des phénomènes anorexiques ou boulimiques, même en l'absence de traitement anti-dépression. Parmi les causes génétiques des pathologies précédentes, il faut citer les populations des groupes HLA-DQ2 (DRB1/DQB1) et/ou DQ8. Les sérotypes HLA-DQ2 et HLA-DQ8 sont des sérotypes du groupe HLA-DQ. Preferably, the proteins used are anti-HIV protease inhibitors. Other types of protease inhibitors, including active HCV inhibitors, can also be used. These products, which are currently marketed mainly in anti-HIV tritherapies, have proved, in a preliminary study of women with repeated abortions, to have significant effects in reducing these miscarriages by restoring normal fertility. In the field of the treatment of TCA when these are of genetic origin, in particular having an immunological component, there is a net decrease in anorexic or bulimic phenomena, even in the absence of anti-depression treatment. Among the genetic causes of the preceding pathologies, it is necessary to mention the populations of the HLA-DQ2 (DRB1 / DQB1) and / or DQ8 groups. The serotypes HLA-DQ2 and HLA-DQ8 are serotypes of the HLA-DQ group.
Dans ces conditions, en cas d'avortements à répétition, on sélectionnera, pour bénéficier du traitement à base d'inhibiteurs de protéases, de préférence des femmes ayant des groupes HLA-DQ2, notamment DQ2 (DRB1/DQB1) et/ou DQ8. Les procédés pour le dosage de ces groupes sont connus et ne seront pas rappelés ici. Des essais complémentaires permettront de mettre en évidence des groupements HLA encore plus spécifiques pour le traitement en cause. Dans un certain nombre de cas, ces avortements spontanés peuvent être liés à des pathologies, notamment à des maladies coeliaques sous formes atypiques ou frustres. Il faut rappeler que les formes atypiques ou frustres de la maladie coeliaque se caractérisent par des anémies en fer, en folate, en vitamine B12, des hypertransaminasémies avec des hépatopathies pouvant aller jusqu'à des hépatopathies sévères, des aphtes récidivants et des symptômes qui peuvent mimer des troubles fonctionnels intestinaux. Ces formes atypiques sont souvent méconnues et/ou confondues avec d'autres pathologies et ne permettent pas toujours la détection de la maladie coeliaque et parfois ne permettent pas de traiter ou prévenir les avortements à répétition. D'autres maladies d'origine génétique et/ou immunologique peuvent être impliquées dans les avortements à répétition et bénéficier des traitements utilisant les inhibiteurs de protéases, notamment la maladie de Crohn. Parmi les inhibiteurs de protéases utilisables, il faut citer : Amprénavir Atazanavir Darunavir Fosamprénavir Indinavir Lopinavir + ritonavir Nelfinavir Ritonavir Saquinavir Tipranavir. Under these conditions, in the case of repeated abortions, women who have HLA-DQ2 groups, in particular DQ2 (DRB1 / DQB1) and / or DQ8, should preferably be selected for treatment based on protease inhibitors. The methods for the assay of these groups are known and will not be repeated here. Further tests will make it possible to identify HLA groups that are even more specific for the treatment in question. In a number of cases, these spontaneous abortions can be linked to pathologies, especially celiac diseases in atypical or frustrated forms. It should be remembered that atypical or frustrated forms of celiac disease are characterized by anemia in iron, folate, vitamin B12, hypertransaminasemias with liver diseases that can lead to severe liver disease, recurrent canker sores, and symptoms that may occur. to mimic intestinal functional disorders. These atypical forms are often unrecognized and / or confused with other pathologies and do not always allow the detection of celiac disease and sometimes do not treat or prevent repeated abortions. Other diseases of genetic and / or immunological origin may be involved in repeat abortions and benefit from treatments using protease inhibitors, including Crohn's disease. Among the protease inhibitors that can be used are: Amprenavir Atazanavir Darunavir Fosamprenavir Indinavir Lopinavir + ritonavir Nelfinavir Ritonavir Saquinavir Tipranavir.
De nombreux autres inhibiteurs de protéases ont été décrits, dans le cas présent, à la différence des traitements antiviraux, il n'existe pas de risque de résistance et donc des multithérapies ne sont pas, en principe, nécessaires. Néanmoins, une association de plusieurs inhibiteurs de protéases peut, dans certains cas, améliorer le traitement des pathologies en cause. Il existe, bien entendu, d'autres dérivés antiprotéases qui peuvent être utilisés dans le cadre de la présente invention, ceux-ci sont décrits dans de nombreuses publications scientifiques et brevets sans qu'il soit nécessaire d'en donner une liste plus exhaustive ci-après. Many other protease inhibitors have been described, in this case unlike antiviral treatments, there is no risk of resistance and therefore multi therapies are not, in principle, necessary. Nevertheless, a combination of several protease inhibitors may, in certain cases, improve the treatment of the pathologies in question. There are, of course, other antiprotease derivatives which can be used in the context of the present invention, these are described in numerous scientific publications and patents without it being necessary to give a more exhaustive list thereof. -after.
De façon générale, les formes d'administration des antiprotéases, notamment les antiprotéases mentionnées précédemment, seront des formes orales et/ou parentérales dans les cas notamment où un risque d'avortement élevé est à prendre en compte, quant aux doses, elles pourront variées, de préférence entre 100 et 1 500 mg par jour, des doses supérieures pouvant être envisagées sous contrôle médical. In general, the forms of administration of the protease inhibitors, in particular the protease inhibitors mentioned above, will be oral and / or parenteral in the cases in particular where a high risk of abortion is to be taken into account, as regards the doses, they may be varied. preferably between 100 and 1500 mg per day, higher doses that can be considered under medical supervision.
Parmi les formes orales, on peut citer les comprimés et gélules, mais surtout les formes liquides qui permettent plus facilement d'ajuster le traitement. Les traitements correspondants sont, de préférence, des traitements qui peuvent être d'une durée assez limitée, notamment de l'ordre de quelques mois, pour assurer une fécondité normale et qui pourront dans certains cas être prolongés au cours de la grossesse sous contrôle médical. Oral forms include tablets and capsules, but especially liquid forms that make it easier to adjust the treatment. The corresponding treatments are preferably treatments which can be of a fairly limited duration, in particular of the order of a few months, to ensure normal fertility and which may in some cases be prolonged during pregnancy under medical supervision. .
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0951105A FR2942409B1 (en) | 2009-02-20 | 2009-02-20 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0951105A FR2942409B1 (en) | 2009-02-20 | 2009-02-20 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2942409A1 true FR2942409A1 (en) | 2010-08-27 |
| FR2942409B1 FR2942409B1 (en) | 2013-07-26 |
Family
ID=41129226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0951105A Expired - Fee Related FR2942409B1 (en) | 2009-02-20 | 2009-02-20 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2942409B1 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2761992A1 (en) * | 1997-04-09 | 1998-10-16 | Hoechst Marion Roussel Inc | NOVEL 4-HALOGEN STEROIDS, PROCESS AND PREPARATION INTERMEDIATES, THEIR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME |
| FR2778337A1 (en) * | 1998-05-05 | 1999-11-12 | Inst Nat Sante Rech Med | ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS |
| WO2002083722A2 (en) * | 2001-04-12 | 2002-10-24 | Academisch Ziekenhuis Leiden | Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides |
| WO2004006959A1 (en) * | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
| WO2004058269A1 (en) * | 2002-12-27 | 2004-07-15 | Ernest Loumaye | Use of gnrh agonists to support the luteal phase during infertility treatment |
| WO2007089733A2 (en) * | 2006-01-27 | 2007-08-09 | Duramed Pharmaceuticals, Inc. | Regimens for treatment of conditions related to estrogen deficiency |
| WO2007088476A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist |
| WO2007100374A2 (en) * | 2005-12-19 | 2007-09-07 | Trustees Of Tufts College | Soft protease inhibitors and pro-soft forms thereof |
-
2009
- 2009-02-20 FR FR0951105A patent/FR2942409B1/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2761992A1 (en) * | 1997-04-09 | 1998-10-16 | Hoechst Marion Roussel Inc | NOVEL 4-HALOGEN STEROIDS, PROCESS AND PREPARATION INTERMEDIATES, THEIR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME |
| FR2778337A1 (en) * | 1998-05-05 | 1999-11-12 | Inst Nat Sante Rech Med | ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS |
| WO2002083722A2 (en) * | 2001-04-12 | 2002-10-24 | Academisch Ziekenhuis Leiden | Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides |
| WO2004006959A1 (en) * | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
| WO2004058269A1 (en) * | 2002-12-27 | 2004-07-15 | Ernest Loumaye | Use of gnrh agonists to support the luteal phase during infertility treatment |
| WO2007100374A2 (en) * | 2005-12-19 | 2007-09-07 | Trustees Of Tufts College | Soft protease inhibitors and pro-soft forms thereof |
| WO2007089733A2 (en) * | 2006-01-27 | 2007-08-09 | Duramed Pharmaceuticals, Inc. | Regimens for treatment of conditions related to estrogen deficiency |
| WO2007088476A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2942409B1 (en) | 2013-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Semet et al. | The impact of drugs on male fertility: a review | |
| Zhang et al. | Regulation of macrophage activation and inflammation by spermine: a new chapter in an old story | |
| Adorini et al. | Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases | |
| Cvjetićanin et al. | Dried leaf extract of Olea europaea ameliorates islet-directed autoimmunity in mice | |
| Gentili et al. | Selective CB2 inverse agonist JTE907 drives T cell differentiation towards a Treg cell phenotype and ameliorates inflammation in a mouse model of inflammatory bowel disease | |
| Dehhaghi et al. | The role of kynurenine pathway and NAD+ metabolism in myalgic encephalomyelitis/chronic fatigue syndrome | |
| Rafe et al. | Preventive role of resveratrol against inflammatory cytokines and related diseases | |
| Brazão et al. | Melatonin and zinc treatment: distinctive modulation of cytokine production in chronic experimental Trypanosoma cruzi infection | |
| Sakai et al. | Lactobacillus pentosus strain S-PT84 improves steatohepatitis by maintaining gut permeability | |
| Matsumoto et al. | Intravenous cyclophosphamide for gastric antral vascular ectasia associated with systemic sclerosis refractory to endoscopic treatment: A case report and review of the pertinent literature | |
| Jung et al. | Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration | |
| EP1083898B1 (en) | Novel use of hiv protease inhibiting compounds | |
| Daei Sorkhabi et al. | Vitamin supplementation as a potential adjunctive therapeutic approach for COVID-19: biological and clinical plausibility | |
| Rezapour-Firouzi et al. | The potential effects of hemp seed/evening primrose oils on the mammalian target of rapamycin complex 1 and interferon-gamma genes expression in experimental autoimmune encephalomyelitis | |
| Li et al. | B cells from old mice induce the generation of inflammatory T cells through metabolic pathways | |
| Mahmoud et al. | The possible protective effect of Omega 3 fatty acids against Bisphenol A induced disruption of pituitary-testicular axis in albino rat. Biohemical, Histological and Immunohistochemical study | |
| Persson et al. | Reflections upon immunological mechanisms involved in fertility, pregnancy and parasite infections | |
| FR2942409A1 (en) | Use of at least one protease inhibitor for the prevention of primary or secondary amenorrhea, infertility, repeated abortions and eating disorders, where the disorders are e.g. associated with atypical/frustrated with celiac disease | |
| Martinelli et al. | Clinical course of focal segmental glomerulosclerosis associated with hepatosplenic schistosomiasis mansoni | |
| US20190105355A1 (en) | Fertilized egg isolate and uses thereof | |
| Takeshita et al. | Dynamics and reproductive effects of complement factors in the spontaneous abortion model of CBA/J× DBA/2 mice | |
| Rosman et al. | Venom immunotherapy in high-risk patients: the advantage of the rush build-up protocol | |
| Zepeda et al. | Vitamin d supplementation in inflammatory bowel disease: a narrative review | |
| da Costa et al. | Effects of nutrients on immunomodulation in patients with severe COVID-19: Current knowledge | |
| Rezapour-Firouzi et al. | Hemp seed/evening primrose oil affects expression of STAT3, IL-17, and FOXP3+ in experimental autoimmune encephalomyelitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 8 |
|
| PLFP | Fee payment |
Year of fee payment: 9 |
|
| PLFP | Fee payment |
Year of fee payment: 10 |
|
| PLFP | Fee payment |
Year of fee payment: 12 |
|
| PLFP | Fee payment |
Year of fee payment: 13 |
|
| PLFP | Fee payment |
Year of fee payment: 14 |
|
| ST | Notification of lapse |
Effective date: 20231005 |